Puma Biotechnology
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology, Inc.
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Surging
Puma shares nearly triple on drug news, but options smell 'fishy'
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology - Updates, News, Events, Signals & Triggers
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Inc (NASDAQ:PBYI) Share Price | RNS News, Quotes, & Charts | PBYI
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology - STAT
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
